Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Zh Nevrol Psikhiatr Im S S Korsakova ; 123(10): 123-128, 2023.
Article in Russian | MEDLINE | ID: mdl-37966451

ABSTRACT

Multiple sclerosis (MS) is a chronic autoimmune progressive demyelinating disease of the central nervous system, mainly in young people. The clinical picture of MS has a variety of neurological symptoms, which manifests itself during periods of exacerbation or progression and stabilizes at the moments of remission. The widespread introduction of new drugs with immunosuppressive and immunomodulatory mechanisms of action has led to the development of special risk management plans for monitoring patients during therapy and preventing adverse events and new comorbid conditions. This article presents a review of the literature and a case report on the combination of MS and melanoma in patients. Melanoma can rarely develop in patients treated with DMD, so it is necessary to introduce such a specialist in dermatology and venereology into a multidisciplinary team.


Subject(s)
Melanoma , Multiple Sclerosis , Humans , Adolescent , Multiple Sclerosis/complications , Multiple Sclerosis/drug therapy , Melanoma/chemically induced , Melanoma/drug therapy , Immunosuppressive Agents/therapeutic use
2.
Kardiologiia ; 60(3): 96-101, 2020 Mar 18.
Article in Russian | MEDLINE | ID: mdl-32375621

ABSTRACT

Chronic noninfectious diseases (cardiovascular, bronchopulmonary, oncological diseases and diabetes mellitus) are presently the most common cause of death worldwide, with cardiovascular diseases (CVD) being predominant. For this reason, the key goal of a physician is not only to treat but also to prevent diseases. Acetylsalicylic acid (ASA) is considered one of the most effective drugs for secondary prevention of CVD. However, the use of ASA for primary prevention is still debated. Results of many studies of ASA are inconsistent. Some studies have suggested that using ASA in patients aged 40-70 with a high 10-year risk of CVD and a low risk of bleeding may reduce the incidence of CVD. Administration of ASA to patients with a high or medium risk of CVD is also considered.


Subject(s)
Aspirin/therapeutic use , Cardiovascular Diseases , Noncommunicable Diseases , Adult , Aged , Humans , Middle Aged , Noncommunicable Diseases/prevention & control , Platelet Aggregation Inhibitors/therapeutic use , Primary Prevention , Secondary Prevention
SELECTION OF CITATIONS
SEARCH DETAIL
...